```json
{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in leucine-rich repeat kinase 2 (LRRK2) are a frequent cause of late-onset autosomal dominant Parkinson's disease (PD).",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as related to Parkinson's disease, with LRRK2 mutations affecting kinase activity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Using an in vitro kinase activity assay, we demonstrate that at ATP concentrations close to cellular levels (1 mM) I2020T is approximately 10-fold more resistant to ATP-competitive kinase inhibitors than wild-type.",
          "judgment": "Yes",
          "reasoning": "The kinase activity assay is a standard method to assess the functional impact of kinase mutations, reflecting disease pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_step": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Kinase reactions were performed in duplicate at room temperature in Kinase Buffer S.",
          "judgment": "Yes",
          "reasoning": "The paper mentions that reactions were performed in duplicate, indicating basic replication, and uses wild-type as a control.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_step": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The affinities of several ATP-competitive kinase inhibitors for wild-type, I2020T, and G2019S were determined.",
          "judgment": "No",
          "reasoning": "The paper does not mention the use of known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The I2020T variant shows altered kinase activity and resistance to inhibitors, suggesting a pathogenic role, but lacks variant controls for stronger evidence."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The G2019S mutation is the most common known genetic cause of PD and is associated with familial and to a lesser extent non-familial cases.",
          "judgment": "Yes",
          "reasoning": "The paper defines the G2019S mutation as a common cause of Parkinson's disease, affecting kinase activity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "G2019S has higher activity in kinase activity assays and was recently shown to have an altered ATP K m,app.",
          "judgment": "Yes",
          "reasoning": "The kinase activity assay is applicable as it reflects the disease mechanism of altered kinase function.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_step": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Kinase reactions were performed in duplicate at room temperature in Kinase Buffer S.",
          "judgment": "Yes",
          "reasoning": "The paper includes basic replication and uses wild-type as a control.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_step": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The affinities of several ATP-competitive kinase inhibitors for wild-type, I2020T, and G2019S were determined.",
          "judgment": "No",
          "reasoning": "The paper does not mention the use of known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The G2019S variant shows increased kinase activity, suggesting a pathogenic role, but lacks variant controls for stronger evidence."
    }
  ]
}
```